Clareo Health | Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab
Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Millennium Pharmaceuticals, Inc.
With
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female subjects 18 years or older
Histologically proven diagnosis of follicular non-Hodgkin's lymphoma grades 1or 2 according to the World Health Organization classification
Subjects must have received at least 12 doses (375mg/m2 or appropriately adjusted dose) of rituximab for the treatment of this lymphoma as single agent rituximab or in rituximab-containing regimens as documented in the subject's medical record
Documented relapse or progression following last antineoplastic treatment
At least 1 measurable tumor mass (≥1.5 cm x ≥1.0 cm)
You may not be if
Subjects with histological or clinical transformation to an aggressive lymphoma
* prior treatment with VELCADE or fludarabine.
* antineoplastic (including unconjugated therapeutic antibodies), experimental, or radiation therapy within 3 weeks before randomization
* nitrosoureas within 6 weeks before randomization
* radioimmunoconjugates or toxin immunoconjugates within 10 weeks before randomization
* major surgery within 3 weeks before randomization
* chronic use of corticosteroids, such as dexamethasone
